902P Quality of life and response to treatment with ixazomib-lenalidomide-dexamethasone (IRd) in patients with relapsed/refractory multiple myeloma (RRMM) in a real-world setting

Autor: Ionova, T., Anchukova, L., Dubov, S., Esenina, T., Ivanova, L., Kaplanov, K., Kochkareva, Y., Kopylova, A., Kravchuk, T., Levanov, A., Li, O., Nikitina, T.P., Rukavitsyn, O., Saraeva, N., Savinova, M., Shelekhova, T., Simashova, P., Shirokova, M., Vinogradova, O., Volkova, S.
Zdroj: In Annals of Oncology September 2020 31 Supplement 4:S655-S655
Databáze: ScienceDirect